This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This research often includes assessing the financial performance, market potential, competitive landscape, regulatory environment and growth potential of target healthcare companies, drugs, medical technologies, treatments and more.
Below, we explore the factors constraining venture capital funding into the first half of the year, and the ways investors can leverage crucial market intelligence to gain a competitive advantage in the shifting landscape. The VC Funding Dryspell Venture capital investment fell to the lowest activity in nearly five years for Q1 2024.
These intangible factors indicate that even the most exhaustive duediligence processes can still leave gaps in the M&A research process. Comprehensive DueDiligence Thorough duediligence on a target company is undeniably the cornerstone of successful M&A.
Without an official system to check an organization’s commitment to its ESG policies, many shareholders and investors are doing their duediligence through fact-checking. timber, natural pharmaceuticals) and services (i.e., In fact, biodiversity attrition can also severely hinder a company’s bottom line.
One AlphaSense customer has saved tens of thousands of dollars by using our AI-search technology to optimize their research at various pharmaceutical companies. Expert Networks are Primarily for Market Research Another misconception about expert networks is that they can only be used for market research.
Generally, expert calls provide investment researchers with the operator’s perspective, which is critical to understanding competitive moats and enhancing data-driven research with soft data. You think, ‘I have competitively a better methodology, a better framework, and you think the world will go on it.’ It’s one of those things.
Massive Data Analysis It’s clear that the pharmaceutical industry is increasingly in need of handling and interpreting expansive datasets efficiently and accurately. Adapting to these changes positions biopharma brands advantageously in a competitive landscape, ensuring they remain relevant and visible.
This emerging trend is allowing pharmaceutical companies—large and small—to distinguish themselves among competitors and investors as they pioneer advancements fueled by AI. M&A will serve as an avenue for pharmaceutical companies and start-ups to continue making significant advancements in their respective fields.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content